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Intrastriatal injection of quinolinic acid (QA) provides an
animal model of Huntington disease. In vivo 1H NMR
spectroscopy was used to measure the neurochemical
profile non-invasively in seven animals 5 days after uni-
lateral injection of 150 nmol of QA. Concentration
changes of 16 metabolites were measured from 22 ml
volume at 9.4 T. The increase of glutamine ((125 6 14)%,
mean 6 SD, n 5 7) and decrease of glutamate (212 6
5)%, N-acetylaspartate (217 6 6)%, taurine (214 6 6)%
and total creatine (29 6 3%) were discernible in each
individual animal (P , 0.005, paired t-test). Metabolite
concentrations in control striata were in excellent agree-
ment with biochemical literature. The change in gluta-
mate plus glutamine was not significant, implying a shift
in the glutamate-glutamine interconversion, consistent
with a metabolic defect at the level of neuronal-glial
metabolic trafficking. The most significant indicator of
the lesion, however, were the changes in glutathione
((219 6 9)%, P , 0.002)), consistent with oxidative
stress. From a comparison with biochemical literature we
conclude that high-resolution in vivo 1H NMR spectros-
copy accurately reflects the neurochemical changes in-
duced by a relatively modest dose of QA, which permits
one to longitudinally follow mitochondrial function, oxi-
dative stress and glial-neuronal metabolic trafficking as
well as the effects of treatment in this model of Hunting-
ton disease. J. Neurosci. Res. 66:891–898, 2001.
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Huntington disease (HD) is an autosomal dominant
neurodegenerative disorder characterized by dyskinesia,
cognitive impairment, and emotional disturbances (Sharp
and Ross, 1996; Haque et al., 1997). Among the patho-
genic theories of Huntington disease is the presence of a
defect in oxidative phosphorylation, which is supported by
the observation of elevated lactate concentrations in the
occipital cortex and basal ganglia of HD patients (Jenkins
et al., 1993, 1998), decreased cerebral glucose utilization
(Greene and Greenamyre, 1996), and a reduced mito-
chondrial complex II–III activity found in postmortem
brain tissue (Gu et al., 1996; Beal, 2000). Moreover,
treatment of HD patients with the anti-oxidant coenzyme
Q10 (ubiquinone) was reported to significantly lower cor-
tical lactate concentration in patients (Koroshetz et al.,
1997). Furthermore, neuroprotective effects of coenzyme
Q10 (Matthews et al., 1998a) as well as of creatine (Fer-
rante et al., 2000) were described in a transgenic mouse
model of HD. Recent studies have suggested that oxida-
tive stress may also be involved in Huntington disease as
judged from alterations in the metabolism of glutathione
and related enzymes (Tabrizi et al., 1999).
An accepted animal model of HD is based on the
intrastriatal administration of quinolinic acid (Schwarcz et
al., 1983; Beal et al., 1986, 1991), an endogenous metab-
olite of L-tryptophan and agonist of the NMDA-receptor.
In this model, neuronal damage is apparently caused by
overstimulation of glutamate receptors, which can be pre-
vented with NMDA receptor antagonists such as MK-801
(Beal et al., 1988) or kynurenate (Ceresoli-Borroni et al.,
1999). Excessive receptor stimulation results in a loss of
Ca21 homeostasis, which can lead to mitochondrial dys-
function and formation of nitric oxide and other free
radicals (Greene and Greenamyre, 1996) leading to neu-
ronal death via apoptotic and necrotic mechanisms (Ferrer
et al., 1995; Portera-Cailliau et al., 1995). The QA model
produces behavioral and neuroanatomical effects mimick-
ing some of the earlier symptoms of HD (Shear et al.,
1998).
Methods used to assess metabolite concentration
changes in excitotoxic lesions include immunohistochem-
istry (Nakao et al., 1996), radioimmunoassay (Beal et al.,
1986), freeze clamp technique followed by tissue extrac-
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tion and HPLC analysis (Beal et al., 1986; Bordelon et al.,
1997), microelectrodes (Bordelon et al., 1998), and mi-
crodialysis (Reynolds et al., 1997), all of which are inva-
sive and thus not very well suited for longitudinal studies.
Non-invasive microPET imaging was used to assess time
course of alternations in energy utilization and dopamine
receptors in QA-lesioned rat striatum (Araujo et al., 2000).
In vivo NMR spectroscopy is a non-invasive method,
which does not require substrates with isotope labeling.
Only a limited number of metabolites, such as N-acetyl-
aspertate, creatine, and lactate, however, has been quan-
tified with in vivo NMR spectroscopic techniques in
excitotoxic lesions (Jenkins et al., 1996; Strauss et al.,
1997; Matthews et al., 1998b; Lee et al., 2000). Recent
developments in high field in vivo 1H NMR spectroscopy
(Gruetter et al., 1998b) have resulted in the ability to
quantify up to 18 metabolites simultaneously and non-
invasively (Pfeuffer et al., 1999a; Tka´cˇ, et al., 1999). The
aim of our study was to quantify the concentration
changes of at least 15 metabolites simultaneously in QA-
lesioned and contralateral rat striatum and to test the
potential to detect QA induced changes in individual
animals.
Previous biochemical, histological, and behavioral
studies of the QA model of HD have covered wide ranges
in dosage (from 30–500 nmol QA) and time scale (min-
utes to several months). Recent studies focused mainly on
the early post-injection effects (Bordelon et al., 1998;
Bordelon and Chesselet, 1999; Ceresoli-Borroni et al.,
1999; Mena et al., 2000; Rodriguez-Martinez et al.,
2000). We chose a protocol (5 days post-injection,
150 nmol QA dose) because this dose has been shown to
induce significant neuropathology and behavioral deficits
that are amenable to treatment. Because the goal of this
study was to evaluate the usefulness of a new non-invasive
modality that was potentially suitable for longitudinal
monitoring, we focused on a time point (5 days post-
injection) where cell death and degeneration were fairly
well resolved, yet acute enough to allow treatment. In
addition, the QA lesion model provides us with an internal
control: the contralateral striatum, allowing a paired com-
parison between lesioned and control striata in the same
animal, with the potential to follow the effect and pro-
gression of cell transplantation.
MATERIALS AND METHODS
Animals
Experiments were performed according to procedures
approved by the Institutional Review Board’s animal care and
use committee. Ten female Fischer 344 rats (150–200 g) were
used for the study because animal growth in this strain is limited.
Animals were anesthetized with ketamine-xylazine and placed
in a stereotactic frame. Excitotoxic lesions were induced by
injection of buffered solution of quinolinic acid (1 ml,
150 nmol/ml) into the right anterior striatum of seven rats 5 days
before the NMR measurement. Three animals received a larger
QA dose (1 ml, 300 or 450 nmol/ml). During the NMR
experiments, animals were anesthetized by a gas mixture of
O2:N2O 5 3:2 with 1.5% isoflurane. The rats were ventilated at
physiological conditions by a pressure-controlled respirator
(Kent Scientific Corp., Litchfield, CT). Oxygen saturation was
maintained above 95% and was continuously monitored by a
pulse oximeter attached to the tail (Nonin Medical, Inc., Min-
neapolis, MN). Body temperature was maintained at 37°C by
warm water circulation and verified by a rectal thermosensor
(Cole Parmer, Vernon Hills, IL).
1H NMR Spectroscopy
In vivo 1H NMR spectra were measured in the same
session from the QA-lesioned as well as from the contralateral
(control) striatum 5 days after QA was injected into one stria-
tum. 1H NMR spectra were measured at 9.4 T from a 22 ml
volume using a Varian INOVA spectrometer (Varian, Palo Alto,
CA) interfaced to a 9.4 T magnet with 31 cm horizontal bore
size (Magnex Scientific, Abingdon, UK). The actively shielded
gradient coil insert of 12 cm inner diameter (Magnex) was
capable of switching to 300 mT/m within 500 msec. A quadra-
ture surface RF coil consisting of two geometrically decoupled
single turn 1H coils with 14 mm diameter, constructed accord-
ing to a previously described design (Adriany and Gruetter,
1997), was used for transmitting and receiving. A stimulated
echo acquisition mode (STEAM) localization sequence with
very short echo time (TE 5 2 msec, TM 5 5 msec) combined
with outer volume saturation was used (Tka´cˇ, et al., 1999). The
bandwidth of the slice-selective RF pulses was 13.5 kHz, which
ensured that over a 3 ppm range, the chemical shift displacement
error was less than 10%. T1 was assessed to be constant as judged
from the measured metabolite-nulled spectra acquired in each
animal for each striatum using an inversion time on 0.95 sec,
which implies that T1 of metabolites was approximately 1.4 sec.
The repetition time was 4 sec, which minimized effects due to
potential T1 variation. As in our previous study (Pfeuffer et al.,
1999a), metabolite-nulled spectra were used to assess the mac-
romolecule background, which was found to be highly consis-
tent between animals (data not shown). The water signal was
suppressed by variable power RF pulses with optimized relax-
ation delays (VAPOR) as described recently (Tka´cˇ, et al., 1999).
First- and second-order-shimming was performed by a fully
adiabatic version of FASTMAP (fast, automatic shimming tech-
nique by mapping along projections) (Gruetter, 1993; Gruetter
et al., 1998b; Gruetter and Tka´cˇ, 2000) resulting typically in an
11–12 Hz linewidth of the water signal in vivo. T2-weighted
spin echo MR images were obtained for positioning of the
localized volume.
NMR Quantification of Metabolite Concentrations
Metabolite concentrations were quantified by LCModel
(Linear Combination of Model spectra of metabolite solutions)
(Provencher, 1993) as described recently (Pfeuffer et al., 1999a)
by including macromolecule spectra in the fitting procedure and
by using the water signal as an internal reference (assuming a
water content of 0.83 ml/g). Due to the short echo-time of
2 msec, T2 relaxation effects on NMR signal intensity were
assessed to be below 2% and, therefore, neglected. The LC-
Model method of quantifying GABA in human brain at 7 T
(Tka´cˇ, et al., 2001) was compared to homonuclear editing
methods of measuring GABA (Terpstra et al., 2001), which
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provided results that were in excellent agreement within the
experimental error. Sixteen metabolites were quantified from
22 m volume: alanine (Ala), aspartate (Asp), creatine (Cr),
g-aminobutyric acid (GABA), glucose (Glc), glutamate (Glu),
glutamine (Gln), glutathione (GSH), glycerophosphorylcholine
plus phosphorylcholine (GPC1PCho), myo-inositol (Ins), lac-
tate (Lac), N-acetylaspartate (NAA), N-acetylaspartylglutamate
(NAAG), phosphocreatine (PCr), phosphorylethanolamine
(PE), and taurine (Tau). The strongly represented signals of Cr,
PCr, Gln, Glu, Ins, NAA, and Tau were quantified with
Crame´r-Rao lower bounds below 6%. Lac, PE, and the sum of
PCho and GPC were quantified with Crame´r-Rao lower
bounds below 10%, and those of GABA, Glc, and GSH were
below 20%. Metabolite concentrations QA-lesioned striatum
were compared to concentrations in contralateral striatum using
the paired t-test.
RESULTS
1H NMR spectra from the lower dose QA striatal
lesion and from contralateral position are shown in Fig-
ure 1. Due to the high magnetic field and very good
shimming, characteristic multiples of several metabolites,
e.g., myo-inositol (3.53 ppm, 3.62 ppm) and taurine
(3.25 ppm, 3.42 ppm), were resolved. Signals of protons
bound to the C4 of glutamate (2.35 ppm) and glutamine
(2.45 ppm) were clearly distinguishable. Due to a small
chemical shift difference of 0.002 ppm, the methylene
resonances of creatine and phosphocreatine were partially
resolved at 3.9 ppm as in our previous studies (Pfeuffer et
al., 2000, 1999a,b; Tka´cˇ, et al., 1999). The differences
between the spectra measured from the QA lesion and
contralateral striatum, highlighted by the arrows in Figure
1, were clearly discernible in each animal.
The mean values of metabolite concentrations mea-
sured in striatal QA lesions and contralateral positions are
shown in Figure 2. The most significant changes (P ,
0.005, paired t-test) between QA-lesioned and contralat-
eral striata were increased concentration of glutamine ((by
125 6 14)% of control striatum, mean 6 SD)) and
decreased concentrations of glutamate (212 6 5)%,
N-acetylaspartate (217 6 6)%, taurine (214 6 6)%,
glutathione (219 6 9)%, and creatine (211 6 6)%. Total
creatine concentration ([Cr] 1 [PCr]) was decreased by
(29 6 3%). Inter-individual coefficients of variation of
the measured concentrations were small, e.g., below 4%
for total Cr in contralateral striatum, such that the un-
paired t-test also returned statistical significance for all
these changes (P , 0.02). The relative changes in metab-
olite concentrations between QA-lesioned and contralat-
eral striata from each study (n 5 7) are shown in Figure 3.
Increased concentrations of Gln and decreased concentra-
tions of Glu, Cr, GSH, NAA, and Tau in QA-lesioned
relative to contralateral striatum were detected in all seven
rats (Fig. 3). Phosphocreatine was decreased in five of
seven rats (26 6 9%). Glucose concentrations in QA-
lesioned striatum were decreased in six of seven rats and
the concentrations of lactate were increased in five of
seven rats. The intensities of the short T1 background
signals (“macromolecules”) were very stable and the co-
efficient of variation of all fitted values from the spectra of
control striata was 4%. In the lesioned striatum, the mac-
romolecule signal was reduced by (27 6 5)%. None of
the other metabolite changes were strong enough to reach
statistical significance (Table I).
A 1H NMR spectrum measured from a control
striatum and spectra from striatal lesions induced with
increasing QA dose are compared in Figure 4. A higher
dose of quinolinic acid (300 nmol) resulted in more pro-
nounced changes (Fig. 4C) than observed in lesions in-
duced by the smaller QA dose (150 nmol, Fig. 4B) and, in
addition, lipid resonances were detected. When the QA
dose was increased even more (450 nmol), the necrotic
part of the lesion caused strong field inhomogeneity, im-
possible to correct by shimming, which deteriorated the
Fig. 1. In vivo 1H NMR spectra from ipsi- and contralateral striata of
QA-lesioned rat brain (150 nmol dose). STEAM, echo time (TE) 5
2 msec, middle interval (TM) 5 5 msec, repetition time (TR) 5 4 sec,
volume of interest (VOI) 5 22 ml, number of transients (NT) 5 640,
Gaussian line broadening of 1 Hz. Arrows indicate the most significant
changes between the spectra. Assignment of signals: alanine (Ala),
aspartate (Asp), creatine (Cr), g-aminobutyric acid (GABA), glutamate
(Glu), glutamine (Gln), glycerophosphorylcholine (GPC), myo-inositol
(Ins), lactate (Lac), N-acetylaspartate (NAA), phosphocreatine (PCr),
phosphorylcholine (PCho), phosphorylethanolamine (PE), and taurine
(Tau).
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quality of 1H NMR spectra (Fig. 4D) and thus decreased
the accuracy and reliability of quantification. Nevertheless,
it was possible to determine that the concentration of
NAA in Figure 4D was decreased to 1.9 mmol/g, total
creatine to 2.3 mmol/g, taurine to 3.4 mmol/g, glutamate
to 5.5 mmol/g, and the lactate concentration was increased
to 12.7 mmol/g, consistent with necrosis evident from the
increased hyper-intensity on T2-weighted MRI (not
shown).
The average metabolite concentrations in the rat
striatum were calculated using all data from contralateral
striata and striata of healthy rats (first column in Table I).
In addition, average concentration changes between QA-
lesioned and contralateral striatum are presented in the
second column in Table I.
DISCUSSION
Total creatine concentration of (8.1 6 0.3) mmol/g
was in excellent agreement with published data (McIlwain
and Bachelard, 1985). The normal striatal metabolite con-
centrations in Table I are in very good agreement with
biochemical data (Perry, 1982; McIlwain and Bachelard,
1985; Clarke et al., 1989) and in good agreement with
biochemical measurements from the striatum (Jenkins et
al., 2000).
The changes we observed in the QA-lesioned stria-
tum were highly consistent among animals and highly
reproducible, yet rather subtle (on the order of 10%). The
qualitative agreement of the results with previously pub-
lished data emphasize the utility of 1H NMR spectroscopy
to follow disease progression and treatment in this and
possibly other animal models, as well as in patients with
Huntington disease. To achieve such a reproducible mea-
surement, however, several aspects in NMR methodology
need to be emphasized that we considered critical and that
are currently not yet routinely available on commercial
equipment. First, a high-magnetic field (9.4 T) wide-bore
horizontal magnet with a 31 cm clear bore was used and
the magnetic field inhomogeneities were corrected by a
rapid quantitative shimming method (FASTMAP) (Gru-
etter, 1993; Gruetter and Tka´cˇ, 2000) to obtain a high
spectral resolution. In addition, the pulse sequence with
ultra-short echo-time of 2 msec was used to minimize
Fig. 2. Averaged values of metabolite concentrations in low dose
(150 nmol) QA lesions and contralateral striata (n 5 7). Error bars
indicate SD, *P , 0.005, **P , 0.001.
Fig. 3. Relative concentration differences of the metabolites between
ipsi- and contralateral QA-lesioned rat striatum for each measured rat (n
5 7) indicated by different symbol (QA dose: 150 nmol).
TABLE I. Metabolite Concentrations in Rat Striatum and the
Differences Between QA-Lesioned and Contralateral Striata
Determined by LCModel Analysis of In Vivo 1H NMR Spectra
Metabolite
Contralateral striatum
Mean 6 SD (mmol/
g wet weight)
Differences between
QA-lesioned and
contralateral striata
Mean 6 SD (mmol/
g wet weight)
Ala 0.8 6 0.2 20.1 6 0.2
Cr 4.2 6 0.3 20.5 6 0.3*
PCr 3.9 6 0.3 20.3 6 0.4
Glc 2.9 6 0.3 20.3 6 0.5
Gln 3.3 6 0.3 0.8 6 0.5*
Glu 9.1 6 0.5 21.1 6 0.4*
GSH 1.1 6 0.1 20.2 6 0.1*
Ins 4.2 6 0.3 0.1 6 0.3
Lac 3.1 6 1.2 1.0 6 1.5
NAA 7.5 6 0.4 21.3 6 0.5*
NAAG 0.3 6 0.1 0.0 6 0.1
PE 2.7 6 0.5 20.3 6 0.3
Tau 8.1 6 0.8 21.1 6 0.5*
NAA 1 NAAG 7.8 6 0.4 21.4 6 0.4*
GPC 1 PCho 0.9 6 0.1 0.1 6 0.1
Cr 1 PCr 8.1 6 0.3 20.7 6 0.3*
*Paired t-test, P , 0.005.
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J-modulation of coupled spin systems and signal losses.
The high sensitivity of the method resulted in minimal
partial volume effects as evidenced by the small volumes of
22 ml, which were considered adequate for the striatum
for the present pilot study. Given that the changes we
observed were on average half of those reported in the
literature for glutamate, NAA, creatine, taurine and GSH,
it is possible that residual partial volume effects may have
reduced the apparent changes in metabolite concentra-
tions. This effect can be further minimized by reducing
the volume size by 50%, which can be achieved by re-
ducing the localization dimensions by 20%. It remains to
be seen, however, whether gender and or strain can affect
the manifestation of this animal model of HD, as the
majority of studies have used male Sprague–Dawley rats.
At 9.4 T, the spectral pattern was unique for each
metabolite as a fingerprint, which resulted more robust
data. The short T1 background signals, attributed to mac-
romolecules, were included in this analysis (LCModel)
(Provencher, 1993; Pfeuffer et al., 1999a). Macromolecule
signals were highly reproducible, provided excellent sup-
pression of extra-cerebral lipid signals by outer volume
suppression was achieved, which we consistently verified
in our study (Tka´cˇ, et al., 1999). Excellent stability of the
baseline was attributed to the advanced water suppression
methods used (Tka´cˇ, et al., 1999), leading to an almost
negligible water signal in the spectra. Taken together,
these advances lead to the simultaneous quantification of
more than fifteen metabolites non-invasively in the QA-
lesioned and contralateral rat striatum, providing a paired
comparison within each animal. The resulting quantifica-
tion was robust as indicated by the very small inter-
individual variations in measured metabolite concentra-
tions. Total creatine was quantified with Crame´r-Rao
lower bounds of 2% and the coefficient of variation in
non-lesioned striata was below 5%, which can be consid-
ered adequate for most neurochemical applications.
The sum of concentrations ([NAA] 1 [NAAG]) was
reduced in the QA-lesioned striatum in agreement with
previously published NMR data from lesions induced by
QA (Strauss et al., 1997). The decreased NAA concentra-
tion in the QA lesion can by explained by the decreased
NAA concentration in excitotoxically-impaired neurons
as well as the selective loss of neurons in the lesion. The
increased glutamine and decreased glutamate concentra-
tions are in agreement with the results of chemical analysis
of tissue extracts performed 12 hr after QA injection
(Bordelon et al., 1997), although we did not observe such
a substantial decrease in glutamate (Bordelon et al., 1997).
The QA dose and the post-injection time, however, were
not identical. It is also possible that a partial-volume effect,
i.e., the lesion size was smaller than the measured volume
of interest (22 ml), and a spatial heterogeneity of the lesion
(Bordelon and Chesselet, 1999; Brickell et al., 1999) in-
fluenced our data.
Increased steady-state glutamine concentration can
be interpreted as the result of a shifted equilibrium be-
tween Gln production in astrocytes (glutamine synthetase)
and decreased uptake by damaged and dying neurons,
which convert glutamine to glutamate via glutaminase
(Greene and Greenamyre, 1996). The presence of elevated
Gln in the lesion is evidence of a profound metabolic
defect and is in agreement with biochemical extracts from
transgenic mice (Jenkins et al., 2000). The observed in-
crease in glutamine compared to the decrease in glutamate
can be analyzed in terms of the metabolic trafficking
between neurons and glia that occurs during glutamatergic
action (Tsacopoulos and Magistretti, 1996; Daikhin and
Yudkoff, 2000). The changes were highly significant for
both Glu and Gln, however, the change in the sum of
both was 0.3 6 0.6 mmol/g, which was not significant
(P . 0.6). Although the metabolite changes could be
perceived as reflecting a shift in cellular composition of the
tissue examined, the constancy of ([Glu] 1 [Gln]) may also
imply a metabolic shift similar to what has been observed
Fig. 4. Preliminary demonstration of the changes in the 1H NMR
spectra that can potentially be detected with increasing QA dose. From
the striatum of an intact rat (a) compared to the spectra from the striatal
QA lesion induced by increasing QA dose (b) 150 nmol, (c) 300 nmol,
(d) 450 nmol. STEAM, TE 5 2 msec, TM 5 5 msec, TR 5 4 sec,
VOI 5 22 ml, NT 5 640, Gaussian line broadening of 1 Hz. For an
assignment of signals see Figures 2 and 3.
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in ischemia, namely an increased Gln concentration (in
astrocytes) and a decreased (neuronal) glutamate concen-
tration (Aas et al., 1993). Such a metabolic blockade at the
level of the conversion of glutamine to glutamate (or
glutamine transport out of the astrocyte) would imply that
the action of QA on metabolism is indirect, by affecting
the glutamine-glutamate interconversion, which has been
linked to glutamatergic action (Yudkoff et al., 1993; Gru-
etter et al., 1998a; Sibson et al., 1998). Our data suggest
that the conversion of glutamine to glutamate or transport
of glutamine out of the glia and into the neurons are
impaired. Because neurons lack the ability to synthesize
TCA cycle intermediates de novo through anaplerosis,
replenishment of the neurotransmitter glutamate pool
from astrocytic glutamine appears to be inhibited at one of
the many steps involved in converting glial glutamine to
neuronal glutamate.
Interestingly, highly significant changes (P , 0.002)
were detected in brain glutathione. Concentration of GSH
can be measured by 1H NMR spectroscopy (Pfeuffer et
al., 1999a; Trabesinger et al., 1999; Trabesinger and
Boesiger, 2001) and GSH metabolism can be followed
after administration of [1-13C]glucose (Choi and Gruetter,
2000). Glutathione is known as a free radical scavenger
whose concentration has been postulated to reflect mito-
chondrial integrity. The decrease of glutathione (219 6
9%) in the excitotoxic lesion is in excellent agreement
with a recent study measuring a 30 6 10% decrease in
GSH using biochemical extraction 1 week after 225 nmol
QA injection (Cruz-Aguado et al., 2000). The somewhat
smaller decrease in our study (Table I) probably reflects the
smaller dose (150 nmol) used. These results strongly point
to the involvement of oxidative stress possibly associated
with impaired mitochondrial function in the pathogenesis
of the toxin model of HD (Bordelon et al., 1997). De-
creased GSH in QA lesions is also consistent with the
observation that antioxidant treatment (Koroshetz et al.,
1997; Matthews et al., 1998a) protected striatal neurons
against excitotoxic insult, which supports the hypothesis
that free radicals contribute to excitotoxic neuronal injury
(Nakao et al., 1996).
We observed an 8% decrease in striatal GABA con-
centration between QA lesion (150 nmol dose) and con-
tralateral striatum that was not significant due to the 25%
coefficient of variation. Our inability to detect changes in
GABA are not necessarily at odds with the well-
established decrease of GABAergic neurons in the QA-
lesioned striatum, when considering the experimental er-
rors involved. First, only a 25% decrease was reported
2 weeks after administering 150 nmol of QA (Beal et al.,
1986). Second, the scatter in the GABA measurements can
be explained by the difficulties involved in detecting small
changes in the GABA signal, that is comparatively weakly
represented in the 1H spectrum, even at 9.4 T.
The decreased concentration of Tau (214 6 6)%
observed in our study is in agreement with the decrease in
extracellular Tau concentration measured by microdialysis
(Bockelmann et al., 1998) and with an 46% decrease in
Tau concentration measured 7 days after 240 nmol QA
(Ellison et al., 1987). Phosphocreatine was decreased and
lactate was increased in the QA lesions relative to the
contralateral striatum in five of seven rats, which supports
the notion that QA induces impairments in energy me-
tabolism (Bordelon et al., 1997).
Preliminary data indicated that progressively increas-
ing the QA dose induced more pronounced changes in the
1H NMR spectra (Fig. 4C,D), which is in agreement with
dose-dependent changes in metabolite concentrations ob-
served in QA lesions (Beal et al., 1986).
Our study thus illustrates the potential of high-field
in vivo 1H NMR spectroscopy to detect small neuro-
chemical changes in animal models of HD. This emerging
modality can be expected to be very useful in longitudi-
nally assessing fetal graft viability as potential treatments of
HD in animal models and human disease alike.
We conclude that high field in vivo 1H NMR spec-
troscopy can detect changes in the neurochemical profile in
the quinolinic acid-lesioned rat striatum, suitable to monitor
the pathophysiology of the striatum after excitotoxic injury,
and thus provide a better understanding of the neuropatho-
logical processes that underlie neurodegeneration. The ob-
served increase in the concentration of glutamine and
decrease in concentration of phosphocreatine/creatine, glu-
tamate, glutathione, N-acetylaspartate, and taurine are con-
sistent with neuronal cell loss, impaired energy metabolism
and oxidative stress. Furthermore, the increased ratio of
[Glu]/[Gln] in QA lesions indicates an imbalance between
glutamine production in astrocytes and its uptake by damaged
and dying neurons.
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